Market Newsdesk

TORONTO, July 7, 2021 /CNW/ – RBC Global Asset Management Inc. (“RBC GAM Inc.”) today announced June mutual fund net sales of $1.97 billion. Long-term funds had net sales of $2.44 billion and money market funds had net redemptions of $468 million. Mutual fund assets under management increased by 2.5 percent.

“Canadian investors and advisors continue to seek out investment solutions that offer broad diversification,” said Doug Coulter, President of RBC Global Asset Management Inc. “Demonstrating this trend, the RBC Global Portfolios were our top-selling solutions in June and surpassed the milestone of $6 billion in assets under management. This suite of solutions, launched in July, 2019, brings together the investment expertise of our 23 investment teams located around the world, providing investors with actively managed and globally diversified portfolios.”

Mutual fund sales results information is based on preliminary data from the Investment Funds Institute of Canada (IFIC) and only include Canadian prospectus qualified mutual funds.

Please consult your advisor and read the prospectus or Fund Facts document before investing. There may be commissions, trailing commissions, management fees and expenses associated with mutual fund investments. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated. RBC Funds, BlueBay Funds and PH&N Funds are offered by RBC GAM Inc. and distributed through authorized dealers in Canada. RBC GAM Inc. is a member of the RBC GAM group of companies and an indirect wholly owned subsidiary of Royal Bank of Canada.

About RBC
Royal Bank of Canada is a global financial institution with a purpose-driven, principles-led approach to delivering leading performance. Our success comes from the 86,000+ employees who leverage their imaginations and insights to bring our vision, values and strategy to life so we can help our clients thrive and communities prosper. As Canada’s biggest bank, and one of the largest in the world based on market capitalization, we have a diversified business model with a focus on innovation and providing exceptional experiences to our 17 million clients in Canada, the U.S. and 27 other countries. Learn more at rbc.com.‎

We are proud to support a broad range of community initiatives through donations, community investments and employee volunteer activities. See how at rbc.com/community-social-impact.

About RBC Global Asset Management

RBC Global Asset Management (RBC GAM) is the asset management division of Royal Bank of Canada (RBC) and includes money managers BlueBay Asset Management and Phillips, Hager & North Investment Management. RBC GAM is a provider of global investment management services and solutions to institutional, high-net-worth and individual investors through separate accounts, pooled funds, mutual funds, hedge funds, exchange-traded funds and specialty investment strategies. The RBC GAM group of companies manage approximately $550 billion in assets and have approximately 1,500 employees located across Canada, the United States, Europe and Asia.

SOURCE RBC Global Asset Management Inc.

DONGGUAN, China
, July 7, 2021 /PRNewswire/ — Dogness (International) Corporation (“Dogness” or the “Company”) (NASDAQ: DOGZ), a developer and manufacturer of a comprehensive line of Dogness-branded, OEM and private label pet products, today announced it shipped 700 cartons of the Company’s traditional pet products to one of its long-term strategic partners in Japan for sale.  The Company noted it is continuing to benefit from strong demand in key markets worldwide led by China, the U.S., Japan and Europe, with significant growth in other countries including Egypt, Russia, Germany, Panama, Australia and New Zealand.

The population of dogs and cats in Japan (18.13 million) outnumbers that of children 15-years-old or younger (15.3 million). This was attributed in part to the COVID-19 pandemic, during which time the number of new pet owners increased.  The life expectancy of dogs in Japan is 14.5 years, and the life expectancy for cats is roughly 15.5 years. This is attributed to the fact that 84.7% of dogs and 90.4% of cats are kept indoors year-round, resulting in reduced risk of sickness.  (Source: The Japan Pet Food Association)

Silong Chen, Chairman and Chief Executive Officer of Dogness, commented, “Our team has been working closely with our customers and supply chain partners to ensure we can seamlessly meet the high demand levels we are seeing in Japan.  Pet owners are turning to Dogness for high-quality traditional pet products and innovative smart pet tech products that can bring greater happiness, safety and health to their pets.  We take pride in supporting stronger pet and owner bonds.  We expect to build on our momentum with some very exciting new product launches planned for later this year that will leverage advances in tracking, water and food monitoring, robotics and AI.” 

About Dogness

Dogness (International) Corporation was founded in 2003 from the belief that dogs and cats are important, well-loved family members. Through its smart products, hygiene products, health and wellness products, and leash products, Dogness’ technology simplifies pet lifestyles and enhances the relationship between pets and pet caregivers. The Company ensures industry-leading quality through its fully integrated vertical supply chain and world-class research and development capabilities, which has resulted in over 200 patents and patents pending. Dogness products reach families worldwide through global chain stores and distributors. For more information, please visit: ir.dogness.com.

Forward Looking Statements

No statement made in this press release should be interpreted as an offer to purchase or sell any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended, and applicable state securities laws. Certain statements in this press release concerning our future growth prospects are forward-looking statements regarding our future business expectations intended to qualify for the “safe harbor” under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding lingering effects of the COVID-19 pandemic on our customers’ businesses and end purchasers’ disposable income, our ability to meet development, production and shipping targets, our ability to raise capital on any particular terms, fulfillment of customer orders, fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, our ability to realize revenue from expanded operation and acquired assets in China and the U.S., our ability to attract and retain highly skilled professionals, client concentration, industry segment concentration, reduced demand for technology in our key focus areas, our ability to successfully complete and integrate potential acquisitions, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings. These filings are available at www.sec.gov. Dogness may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company’s filings with the Securities and Exchange Commission and our reports to shareholders. In addition, please note that any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of the date of this press release. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dogness-ships-700-cartons-of-traditional-pet-products-to-japanese-partner-301326800.html

SOURCE Dogness International Corporation

NEW YORK, July 7, 2021 /PRNewswire/ — Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that a new patent has been awarded by the U.S. Patent and Trademark Office. Patent number 16/914,399 is entitled: Methods for Inducing Synaptogenesis with Synaptic Growth Factor Activating Compounds.

The patent award claims to: “A method for inducing synaptogenesis in a subject having synaptic loss, the method comprising intravenously administering to the subject a therapeutically effective amount of a synaptic growth factor activating compound to result in an increase in synaptogenesis in said subject.”

“Increasing interest in regenerative therapeutics to reverse the degenerative consequences of Alzheimer’s disease makes this recent patent allowance, that has potential applicability to several candidate drugs, especially relevant and timely. We believe the lead Synaptogenix drug, Bryostatin, engages many of the synaptic growth factors such as BDNF, NGF, IGF, and HGF to induce the growth of fully mature synapses and prevents neuronal death. We believe Bryostatin activates natural pathways in the brain with potential generality for treating many disorders including Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, and Fragile X Mental Retardation syndrome,” commented Dr. Daniel Alkon, President and Chief Scientific Officer. 

About Synaptogenix, Inc.

Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer’s disease. Preclinical studies have also demonstrated Bryostatin’s regenerative mechanisms of action for the rare disease, Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.

Additional information about Synaptogenix, Inc. may be found on its website: www.synaptogen.com. 

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 clinical trial of Bryostatin-1 and further studies, and continued development of use of Bryostatin-1 for AD and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Additional factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company’s patent portfolio, the Company’s inability to expand its business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company’s raw materials, existing or increased competition, stock volatility and illiquidity, and the Company’s failure to implement its business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission. The Company does not undertake to update these forward-looking statements.

Contact information: 

Investors and Media

Investor Relations 
Brett Maas 
Hayden IR 
[email protected] 
(646)536-7331

Robert Weinstein

Chief Financial Officer
Synaptogenix, Inc.
[email protected]

View original content:https://www.prnewswire.com/news-releases/synaptogenix-announces-regenerative-patent-award-to-treat-alzheimers-disease-301326820.html

SOURCE Synaptogenix, Inc.

NEW YORK, July 7, 2021 /PRNewswire/ — S&P Dow Jones Indices announced today that indicated dividend net changes (increases less decreases) for U.S. domestic common stocks increased $12.9 billionduring Q2 2021, compared to $18.0 billion in Q1 2021, $9.5 billion in Q4 2020, –$2.3 billion in Q3 2020, and –$42.5 billion in the COVID-inspired Q2 2020.

For the 12-month June 2021 period, the net dividend rate increased $38.0 billion, compared to a net declined of $22.7 billion for 12-month June 2020 period, as increases were $58.1 billion versus $46.9 billion, and decreases were $20.0 billion compared to $69.6 billion for 2020 period.  

“Dividends are starting to be back in vogue as many companies that suspended their dividends have started to pay again, while others who decreased their dividends or left them unchanged in 2020, have resumed increasing their payments,” said Howard Silverblatt, Senior Index Analyst at S&P Dow Jones Indices. “The overall increase in U.S. common dividends stems from the quick vaccination rate, which has led to significant increases in consumer spending and fueled U.S. record profits and cash-flow.”

Silverblatt continued, “given the general acceptance of the reopening and absent a virus upswing, corporate confidence should continue to improve, as more return to resuming dividend payments and increasing them. At this point, for the S&P 500, 2021 is well on its way to a record payout with a 5% increase in the actual cash payments in shareholders pockets.”

S&P 500 Dividends

On a per share basis, S&P 500 Q2 2021 dividend payments for the S&P 500 decreased 0.7% to $14.58 from Q1 2021’s $14.68 and were up 1.6% from the Q2 2020 $14.35 payment. On an aggregate basis, index components paid $123.4 billion in dividends in the quarter, down from $123.9 billion in Q1 2021 and up from the $119.0 billion in Q2 2020.  For the 12-month June 2021 period, the index paid $57.87 per share, down from the prior period’s $59.68, with an aggregate $484.5 billion to shareholders, compared to $495.5 billion.

Additional findings from S&P Dow Jones Indices’ quarterly analysis of U.S. dividend activity include:

Dividend Increases (defined as either an increase or initiation in dividend payments):

• 568 dividend increases were reported during Q2 2021 compared to 244 during Q2 2020, a 132.8% year-over-year increase.
• Total dividend increases were $15.4 billion for the period, up from $6.7 billion for Q2 2020.
• For the 12-month June 2021, 2,403 issues increased their payments, compared to 2,084 issues for the prior period, a 15.3% increase.
• Total dividend increases for the 12-month June 2021 period were $58.1 billion for the period, up from $46.9 billion for the prior period.

Dividend Decreases (defined as either a decrease or suspension in dividend payments):

• 29 issues decreased dividends during Q2 2021, compared to 639 during Q2 2020, a 95.5% year-over-year decrease.
• Dividend decreases were $2.5 billion for the period, down from $49.2 billion for Q2 2020.
• For the 12-month June 2021 period, 252 issues decreased their dividend payments, compared to 941 decreases during the prior period, a 73.2% decrease.
• Dividend decreases were $15.4 billion for the 12-month 2021 period, an improvement from $27.0 billion for the prior period.

Non-S&P 500 domestic common issues (for issues yielding 10% or less):

• The percentage of non-S&P 500 domestic dividend-paying common issues decreased to 21.0% in Q2 2021, down from 21.4% in Q1 2021, and down from 24.2% in Q2 2020.
• The weighted indicate dividend yield for paying issues was 2.46% in Q2 2021, down from 2.48% in Q1 2021, and down from 3.23% for Q2 2020. The average indicated yield decreased to 2.76% for Q2 2021, down from Q1 2021’s 2.80%, and the 3.28% for Q2 2020.

Large-, Mid-, and Small-Cap Dividends:

• 386 issues, or 76.4%, within the S&P 500 currently pay a dividend, up from 385 for Q1 2021 (76.2%) and up from the 380 which were paying in Q2 2020, as 27 of the 30 members of the Dow Jones Industrial Average^® pay a dividend.
• 63.3% of S&P MidCap 400^®issues now pay a dividend, up from 62.5% for Q1 2021 and up from 58.8% in Q2 2020; 50.4% of S&P SmallCap 600^®issues pay a dividend, up from 49.4% in Q1 2021 and up from 45.8% in Q2 2020.
• Yields across market-cap sizes decreased from Q1 2021 and remained significantly lower than Q2 2020. Large-cap yields decreased to 1.38% (1.47% for Q1 2021 and 1.84% for Q2 2020), mid-caps to 1.20% (1.23% for Q1 2021 and 1.62% for Q2 2020), and small-caps increased to 1.12% (1.11% for Q1 2021 and 1.44% for Q2 2020).
• The yields across dividend-paying market-size classifications were closer, but varied, with large-caps down to 1.88% (1.98% for Q1 2021 and 2.45% for Q2 2020), mid-caps at 1.94% (2.00% for Q1 2021 and 2.67% for Q2 2020) and small-caps at 2.14% (2.14% for Q1 2021 and 2.80% for Q2 2020).

For more information about S&P Dow Jones Indices, please visit www.spdji.com.

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit: www.spdji.com.

View original content:https://www.prnewswire.com/news-releases/sp-dow-jones-indices-reports-us-indicated-dividend-payments-increased-12-9-billion-in-q2-2021–301326844.html

SOURCE S&P Dow Jones Indices

LONDON, July 7, 2021 /PRNewswire/ — Wyndham Hotels & Resorts, the world’s largest hotel franchising company with over 8,900 hotels across nearly 95 countries, today announced the opening of H2 Hotel Budapest, Trademark Collection by Wyndham, the latest addition in Wyndham’s strong portfolio of Trademark properties across Europe and its first property under the Trademark Collection brand in Hungary.  

Located on the eastern side of the Danube River, minutes from the iconic Széchenyi Chain Bridge and within walking distance of many iconic attractions, the 157-room H2 Hotel Budapest is the ideal gateway for travelers looking to explore the rich history and culture of Hungary’s capital city.

The new hotel builds on the Company’s longstanding relationship with H-Hotels.com, a leading hotel operator headquartered in Germany that manages 50 Trademark Collection hotels across key European destinations. H2 Hotel Budapest, Trademark Collection by Wyndham marks the hospitality group’s first hotel outside of Germany, Austria and Switzerland.

Launched in 2017, Trademark Collection by Wyndham is a fast-growing brand, designed and perfectly suited for hoteliers who seek independence on their terms and take pride in their unique spirit, while leveraging the competitive advantages that come with the scale of a global partner such as Wyndham. The H2 Hotel Budapest adds to Trademark Collection’s international growth trajectory over the past four years, bringing its footprint to 115 hotels in countries such as Australia, Austria, Canada, Curacao, Germany, Mexico, Sint Maarten, Switzerland, and the United States. Earlier this year, the brand also launched a first-in-market property in Belgium and a new private island beach resort in Belize. It is set to continue its global growth with additional openings in Germany and Belize.

Christian Michel, Vice President for Development in Europe, Wyndham Hotels & Resorts said: “The Trademark Collection by Wyndham brand has been instrumental in our overall growth strategy in Europe and around the world. We are thrilled to be expanding the brand into such an exciting destination like Hungary while simultaneously supporting our overall conversion strategy. Our relationship with H-Hotels.com has been key in the development of our Trademark by Wyndham Collection across Europe and we look forward to continuing our fruitful collaboration to bring the brand to even more travelers.”

Alexander Fitz, CEO, H-Hotels.com added: “Budapest is a world-renowned European city with beautiful architecture and historical sites, and we are thrilled to have our first H-Hotel outside of Germany, Austria and Switzerland in this metropolitan capital. The new opening marks an exciting step for H-Hotels.com in partnership with Wyndham Hotels & Resorts as we continue to expand our offerings across Europe under the Trademark Collection by Wyndham brand. We look forward to continuing this momentum with two Trademark Collection by Wyndham openings in Dusseldorf slated to open in the second half of this year.”

H2 Hotel Budapest, Trademark Collection by Wyndham is situated in Pest, one of the city’s best areas to take in its rich history, with many iconic attractions nearby such as the UNESCO World Heritage Site, which includes Castle Hill and Buda Castle. The city is also home to the Budapest History Museum, Hungarian National Gallery, and the Fisherman’s Bastion monument with its stunning panoramic views. The property is situated close to the funicular railway, connecting guests to many other popular attractions in the city.

After a busy day exploring the city, guests can enjoy the hotel’s high-quality amenities, including the modern on-site restaurant, H2 Hub, and spacious guest rooms featuring modern design and heated floors. With a dedicated business centre and free high-speed WiFi, the hotel offers a comfortable stay for leisure and business travel. The property has easy access to Budapest International Airport and offers convenient on-site parking.

The H2 Hotel Budapest, Trademark Collection by Wyndham complements the Ramada by Wyndham Budapest City Centre, which opened last year, bringing even more accommodation options to Hungary’s capital city for every type of traveller. 

Wyndham hotels in Hungary and around the world participate in Wyndham Rewards®, the world’s most generous rewards programme with thousands of hotels, vacation club resorts and vacation rentals worldwide. Designed for the everyday traveler, members earn a guaranteed 1,000 points with every qualified stay and may redeem points for a wide range of rewards, including free nights, gift cards, merchandise and more.

About Trademark Collection by Wyndham
Each of Trademark Collection by Wyndham’s upper-midscale-and-above hotels around the world – from landmark hotels in Germany and Switzerland to its flagship hotel, The Galt House Hotel in Louisville, Ky. – boast three common attributes: character, charm, and individuality. Launched in 2017, Trademark Collection is the first soft-brand geared to three- and four-star hotel owners passionate about upholding their hotels’ independent spirit and designed for everyday travellers seeking distinctive, attainable accommodations in sought-after destinations. For more information, visit www.wyndhamhotels.com/trademark. 

About Wyndham Hotels & Resorts
Wyndham Hotels & Resorts (NYSE: WH) is the world’s largest hotel franchising company by the number of properties, with over 8,900 hotels across nearly 95 countries on six continents. Through its network of approximately 797,000 rooms appealing to the everyday traveller, Wyndham commands a leading presence in the economy and midscale segments of the lodging industry. The Company operates a portfolio of 21 hotel brands, including Super 8®, Days Inn®, Ramada®, Microtel®, La Quinta®, Baymont®, Wingate®, AmericInn®, Hawthorn Suites®, Trademark Collection®, Wyndham® and Registry Collection Hotels^SM. Wyndham Hotels & Resorts is also a leading provider of hotel management services. The Company’s award-winning Wyndham Rewards loyalty program offers 87 million enrolled members the opportunity to redeem points at thousands of hotels, vacation club resorts and vacation rentals globally. For more information, visit www.wyndhamhotels.com.

About
 H-Hotels.com
The leading hotel operator is based in Bad Arolsen in Hesse and has around 3,000 employees, employed under the brands Hyperion, H4 Hotels, H+ Hotels, H2 Hotels. H.omes and H.ostels, which are sold under the umbrella brand H-Hotels.com. According to a nationwide customer survey carried out by ServiceValue, H-Hotels.com was awarded the “highest customer loyalty” rating in February 2021 and the Seal of quality “Prize Winner – Sustainable Commitment” with the “Predicate Test Winner” excellent. The constantly growing hotel group is currently in a total of 50 different locations across Germany, Austria and Switzerland and are represented by about 60 hotels. For more information visit www.h-hotels.com/en.

This press release contains “forward-looking statements” within the meaning of U.S. federal securities laws, including the expected addition of hotels and similar statements concerning possible future results or performance. You are cautioned not to place undue reliance on these forward-looking statements, which are not guarantees of future results or performance, speak only as of the date of this press release and are subject to numerous risks and uncertainties, including the risks described in Wyndham Hotels’ most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission, any of which could cause actual results or performance to be materially different from the future results or performance expressed or implied by such forward-looking statements.  Except as required by law, Wyndham Hotels undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, subsequent events or otherwise.

Contact:

Silvia de Candia

Wyndham Hotels & Resorts EMEA
[email protected] 

Scott Carman

Wyndham Hotels & Resorts, Inc.
+1 (973) 753-6590
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/wyndham-continues-growth-of-trademark-collection-in-europe-with-introduction-in-hungary-301326809.html

SOURCE Wyndham Hotels & Resorts

Economic Model Based on PRODIGY Trial Data Demonstrates Continuous Pulse Oximetry and Capnography Monitoring of High-Risk Patients May Reduce Hospital Costs by Over $500,000 Annually

DUBLIN, July 7, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of an economic model based on data from the PRODIGY trial (PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY) that demonstrates shorter patient stays and reduced hospital costs associated with continuous pulse oximetry and capnography monitoring for patients receiving opioids on medical-surgical units when compared to intermittent pulse oximetry alone. According to study findings, continuous capnography and pulse oximetry monitoring of high-risk patients who are receiving opioids could result in $535,531 annual hospital cost savings for a median-sized U.S. hospital and a cumulative patient length of stay decrease of 103 days per year, assuming respiratory depression is decreased by 20%.

Pulse oximetry is a simple, noninvasive bedside technology that can accurately measure changes in arterial blood oxygen saturation and pulse rate. Capnography measures exhaled carbon dioxide during the respiration cycle as well as respiratory rate.

Published online in the May 2021 issue of Advances in Therapy, the analysis was based primarily on data from the PRODIGY trial. PRODIGY is a Medtronic-sponsored, prospective observational, multi-center study conducted to quantify the incidence of and identify patients at high risk for opioid-induced respiratory depression (OIRD), a potentially life-threatening form of respiratory compromise (RC) that reduces the patient’s drive to breathe.

“Although respiratory depression occurs in 46% of patients receiving opioids on the general care floor, the cost-benefit of capnography and oximetry for continuous monitoring of patients had not yet been examined,” said Ashish K. Khanna, M.D., primary study investigator and an associate professor of Anesthesiology, vice-chair for Research, and intensivist at the Wake Forest School of Medicine. “Our findings suggest that compared to intermittent monitoring, investing in continuous monitoring of high-risk patients receiving opioids could reduce the cost burden and length of patient stay while potentially increasing patient safety. Our model suggests that a mere reduction of 1.5% in the incidence of respiratory depression would allow hospital systems to recover costs associated with the investment in monitoring. The expected reduction from deployment of continuous monitoring on hospital floors is way more.”

The economic model was designed using a decision tree framework simulating costs and outcomes of continuous Nellcor™ pulse oximetry and Microstream™ capnography monitoring* versus intermittent pulse oximetry monitoring* for patients at high risk, high and intermediate risk, and any risk of respiratory depression based on their PRODIGY score. Patients’ PRODIGY score was derived from five independent patient characteristics — age, gender, sleep-disordered breathing, opioid naivety, and chronic heart failure. The model applied the results of the PRODIGY study to a hypothetical median-sized U.S. hospital with 2,447 patients receiving opioids on a medical surgical floor in a given year.

“Respiratory compromise is a common, costly, potentially deadly — and preventable — condition. RC is a leading cause of ICU admissions and is one of the key contributing factors for code blues,^1,2” said Frank Chan, president of the Patient Monitoring business, which is part of the Medical Surgical Portfolio at Medtronic. “Medtronic has a deep-rooted history of discovering, developing, and commercializing transformative treatment options for patients globally. As RC continues to be studied, we are able to analyze these learnings and design innovative solutions to help physicians better care for their patients who may experience OIRD.”

Additionally, the primary objective of the PRODIGY trial was to develop and validate a risk stratification tool to assist clinicians in the identification of high risk patients receiving opioids.³ The PRODIGY risk stratification tool may support the recent updates from The Joint Commission on monitoring of post-operative patients receiving opioids with the requirement of putting in place a mechanism to identify high risk patients.⁴

For additional information about the PRODIGY clinical trial, please visit: medtronic.com/prodigy.

About Respiratory Compromise

Respiratory compromise is a potentially life-threatening, progressive condition negatively impacting a person’s ability to breathe adequately to maintain oxygenation and carbon dioxide removal. Patients with respiratory depression may experience shallow, slow, or no breathing after opioid administration which undetected can lead to cardiopulmonary arrest and death.⁵ This condition is rapidly becoming the third-most costly hospital inpatient expense in the U.S., and dramatically increases the likelihood of adverse patient outcomes and cost of patient care.⁶ Not only is respiratory compromise common and dangerous, it has been very difficult to predict.^7,8,9

About the Patient Monitoring Operating Unit at Medtronic


The Patient Monitoring business at Medtronic is working together with the global healthcare community to solve clinically meaningful problems, with technologies and solutions for blood oxygen management, respiratory compromise, and perioperative complications.

About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Pulse oximetry and capnography monitoring systems should not be used as the sole basis for diagnosis or therapy and are intended only as an adjunct in patient assessment.

* Continuous pulse oximetry and capnography device pricing assumptions used list pricing for the following: a Capnostream™ portable respiratory monitor prorated over 7 years; a Microstream™ capnography filterline, and a disposable Nellcor™ pulse oximetry sensor, resulting in $52.73 in device costs per continuously monitored patient stay on a medical surgical floor. For intermittent pulse oximetry monitoring, device pricing consisted of a multiparameter monitor prorated over 7 years and a reusable pulse oximetry sensor, resulting in $0.68 in device costs per patient stay. Additional information on pricing and assumptions are available in the study publication.

¹ Schein RM, Hazday N, Pena M, Ruben BH, Sprung CL. Clinical antecedents to in-hospital cardiopulmonary arrest. Chest. 1990; 98(6):1388–1392.
² Fecho K, Jackson F, Smith F, OverdykF. In-hospital resuscitation: opioids and other factors influencing survival. Ther Clin Risk Manag. 2009;5:961–968.
³ Khanna AK, Bergese S, Jungquist CR, et al. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. Anesth Analg. 2020;131:1012-1024.
⁴ https://www.jointcommission.org/standards/standard-faqs/hospital-and-hospital-clinics/leadership-ld/000002161/
⁵ Morris TA, Gay PC, MacIntyre NR, et al. Respiratory compromise as a new paradigm for the care of vulnerable hospitalized patients. Respir Care. 2017 Apr;62(4):497-512. doi: 10.4187/respcare.05021.
⁶ Wier LM, Henke R, Friedman B. Diagnostic groups with rapidly iCosts, by payer, 2001-2007: statistical brief #91. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville MD; June 2010.
⁷ Belcher AW, Khanna AK, Leung S, et al. Long-acting patient-controlled opioids are not associated with more postoperative hypoxemia than short-acting patient-controlled opioids after noncardiac surgery: a cohort analysis. Anesth Analg. 2016;123(6):1471-9.
⁸ Khanna AK, Sessler DI, Sun Z, et al. Using the STOP-BANG questionnaire to predict hypoxaemia in patients recovering from noncardiac surgery: a prospective cohort analysis. Brit J Anaesth. 2016;116(5):632-40.
⁹ Sun Z, Sessler DI, Dalton JE, et al. Postoperative hypoxemia is common and persistent: a prospective blinded observational study. Anesth Analg. 2015;121(3):709-15.

View original content to download multimedia:https://www.prnewswire.com/news-releases/economic-analysis-finds-continuous-monitoring-for-respiratory-depression-may-provide-benefits-to-patients-and-reduce-hospital-costs-301326579.html

SOURCE Medtronic plc

STATEN ISLAND, N.Y., July 7, 2021 /PRNewswire/ — Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) (“Acurx” or the “Company”) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that it has filed a provisional patent application in the United States Patent and Trademark Office (USPTO). The filing of this patent application relates to ibezapolstat and its use to treat C. difficile Infection while reducing the recurrence of the infection, as well as improving the health of the gut microbiome. This is the latest in the series of patent applications that Acrux has filed to protect its proprietary technologies in the field of antimicrobials. Acurx is commencing a Phase 2b clinical trial in patients with CDI (Clostridioides difficile Infection) during the second half of this year after having recently completed a Ph2a clinical trial which demonstrated that 10 of 10 patients with CDI (100%) met the study’s primary and secondary efficacy endpoints of Clinical Cure at end of treatment and Sustained Clinical Cure with no recurrence of CDI at the 28-day follow-up visit.

Acurx continues to pursue protection for its technologies in the United States and internationally. Acurx aims to protect the technology, inventions, know-how, and improvements that are important to the development of its business using the most effective intellectual property instruments.

Robert J. DeLuccia, Executive Chairman of Acurx, stated “We believe that ibezapolstat’s Gram-Positive Selective Spectrum (GPSS™), kills C. difficile, but not other Firmicutes necessary for maintaining a healthy microbiome, and it spares the important Actinobacteria phylum needed for maintaining a healthy microbiome.” He further stated: “This concept of a dual-effect treatment which includes bactericidal activity against C. difficile bacteria while at the same time providing a restorative effect on the microbiome has the potential to position ibezapolstat as an important first-line therapy for CDI.”

David P. Luci, President & CEO of Acurx, stated: “We believe ibezapolstat’s dual effect to effectively treat patients with CDI while simultaneously and dramatically reducing the likelihood of recurrence by restoring the microbiome would be a significant therapeutic advance. This dual effect would substantially reduce CDI recurrences and if this trend continues in later-stage clinical trials, and ibezapolstat is ultimately approved, it could have a dramatically positive impact on patient outcomes and on reducing downstream healthcare costs.” 

About Clostridioides difficile Infection (CDI). According to the 2017 Update (published February 2018) of the Clinical Practice Guidelines for C. difficile Infection by the Infectious Diseases Society of America (IDSA) and Society or Healthcare Epidemiology of America (SHEA), CDI remains a significant medical problem in hospitals, in long-term care facilities and in the community. C. difficile is one of the most common causes of health care-associated infections in U.S. hospitals (Lessa, et al, 2015, New England Journal of Medicine). Recent estimates suggest C. difficile approaches 500,000 infections annually in the U.S. and is associated with approximately 20,000 deaths annually. (Guh, 2020, New England Journal of Medicine). Based on internal estimates, the recurrence rate of two of the three antibiotics currently used to treat CDI is between 20% and 40% among approximately 150,000 patients treated. We believe the annual incidence of CDI in the U.S. approaches 600,000 infections and a mortality rate of approximately 9.3%.

About the Microbiome in Clostridioides difficile Infection (CDI)

C. difficile can sometimes be a normal component of the healthy gut microbiome, but when the microbiome is thrown out of balance, the C. difficile can thrive and cause an infection. After colonization with C. difficile, the organism produces and releases the main virulence factors, the two large clostridial toxins A (TcdA) and B (TcdB). (Kachrimanidou, Microorganisms 2020, 8, 200; doi:10.3390/microorganisms8020200.) TcdA and TcdB are exotoxins that bind to human intestinal epithelial cells and are responsible for inflammation, fluid and mucous secretion, as well as damage to the intestinal mucosa.

About the Ibezapolstat Phase 2 Clinical Trial.
The multicenter, open-label single-arm segment of this study is to be followed by a double-blind, randomized, active-controlled segment comprise the Phase 2 clinical trial designed to evaluate ibezapolstat in the treatment of CDI. Segment 2a of this trial was an open-label cohort of up to 20 subjects from study centers in the United States. In this cohort, all 10 patients with diarrhea caused by C. difficile were treated with ibezapolstat 450 mg orally, twice daily for 10 days. All patients were followed for recurrence for 28± 2 days. Per protocol, after 10 patients of the projected 20 Phase 2a patients completed treatment, the Trial Oversight Committee assessed the safety and tolerability and made recommendation regarding study continuation.  Based on the recommendation of Acurx’s Scientific Advisory Board (SAB), we terminated enrollment in Phase 2a early and are now advancing to Phase 2b. The SAB unanimously supported the early termination of the Phase 2a trial after 10 patients were enrolled in the trial instead of 20 patients as originally planned. The early termination was further based on the evidence of meeting the treatment goals of eliminating the infection (100%), with no recurrences of infection, and with an acceptable adverse event profile. In Segment 2b, approximately 64 additional patients with CDI will be enrolled and randomized in a 1:1 ratio to either ibezapolstat 450 mg every 12 hours or vancomycin 125 mg orally every 6 hours for 10 days and followed for 28 ± 2 days following the end of treatment for recurrence of CDI. The two treatments will be identical in appearance, dosing times, and number of capsules administered to maintain the blind.

About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company’s approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP). For more information, please visit: www.acurxpharma.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the potential of Ibezapolstat, Acurx’s future expectations, plans and prospects, including without limitation, Acurx’s expectations regarding its growth, strategy, progress and timing of its clinical trials, the potential of its antibiotics, and its intellectual property protection. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the possibility that data from clinical trials will be inconsistent with the data observed in subsequent clinical trials, whether ibezapolstat will benefit from the QIDP designation, whether ibezapolstat will advance through the clinical trial process on a timely basis, whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies where approval is sought, whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed, competition from third parties that are developing products for similar uses, Acurx’s ability to obtain, maintain and protect its intellectual property, Acurx’s dependence on third parties for development and manufacture of product candidates including to supply any clinical trials, Acurx’s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations including its clinical trials. Additional detailed information concerning a number of the important factors that could cause actual results to differ materially from the forward-looking information contained in this release is readily available in Acurx’s publicly filed Registration Statement on Form S-1 and will also be included in quarterly, annual and other reports. Acurx disclaims any obligation to update developments of these risk factors or to announce publicly any revision to any of the forward-looking statements contained in this release, or to make corrections to reflect future events or developments.

Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, Co-Founder & Managing Partner 917-533-1469
[email protected]

View original content:https://www.prnewswire.com/news-releases/acurx-announces-filing-of-provisional-patent-application-for-ibezapolstat-to-treat-cdi-while-reducing-recurrence-of-infection-and-improving-the-health-of-the-gut-microbiome-301326841.html

SOURCE Acurx Pharmaceuticals, Inc.

LISHUI, China, July 7, 2021 /PRNewswire/ — Tantech Holdings Ltd (NASDAQ: TANH) (“Tantech” or the “Company”), a clean energy company in China, today announced that its subsidiary, Shangchi Automobile Co., Ltd. (“Shangchi”), fulfilled a new customer order for its medium-sized fuel bus for export to the Middle East.

In addition to licensed EVs including electric buses, Shangchi also produces fuel buses. The company’s major fuel bus products are sleek, diesel midibuses, which have an overall length of 8 meters, two doors and have seats for 19 passengers. Featuring a manual 5 speed transmission and all the luxuries of a high-end bus, the midibus boasts an efficient, luxury travel experience with comfortable seating, USB charging ports, powerful air conditioning and a state-of-the-art air purification system. Shangchi also assembles tailored fuel buses based on customers’ individualized needs.

Mr. Wangfeng Yan, Chief Executive Officer of Tantech, said, “We are very pleased with customer demand levels and the continued diversification of our business. There is continued strong global demand for feature-rich fuel busses capable of transporting large groups of people in a comfortable environment. This is a large, near-term opportunity for us, along with vehicles we are developing with our other teams, including the street sweeper and industrial vehicle market, which will allow us to expand our scale, manufacturing expertise and brand visibility as we work to build value for the Company and shareholders.”  

About Tantech Holdings Ltd

For the past decade, Tantech has been a highly specialized high-tech enterprise producing, researching and developing bamboo charcoal-based products with an established domestic and international sales and distribution network. Since 2017 when the Company acquired 70% of Shangchi Automobile, a vehicle manufacturer based in Zhangjiagang City, Jiangsu Province, it has manufactured and sold vehicles. The Company established two new subsidiaries in November 2020, with the plan to produce and sell street sweepers and other electric vehicles. The Company is fully ISO 90000 and ISO 14000 certified and has received a number of national, provincial and local honors, awards and certifications for its quality products and scientific research efforts.  For more information please visit: http://ir.tantech.cn.

Forward-Looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning the closing of the Private Placement, plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulations, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by this cautionary statement and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

View original content:https://www.prnewswire.com/news-releases/tantech-subsidiary-fulfills-fuel-midibus-order-and-exports-to-the-middle-east-301326730.html

SOURCE Tantech Holdings Ltd.

EDEN PRAIRIE, Minn., July 7, 2021 /PRNewswire/ — NeuroOne Medical Technologies Corporation (NASDAQ: NMTC; NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that the company will present at Access to Giving Virtual Conference.

Registration Details
Date: Thursday, July 15, 2021
Time: 2 p.m. ET
Link: https://access-to-giving.events.issuerdirect.com/signup 

To learn more about the event or to schedule a one-on-one meeting with NeuroOne’s management, please visit https://www.accesstogiving.com/ or email [email protected]. 

About Access to Giving Virtual Conference

Access to Giving is a first-of-its-kind virtual investor conference where companies from microcap all the way up to megacap will have the opportunity to present their story and conduct 1×1 meetings with qualified investors, for charity. Investors will make donations to purchase a block of meetings to meet with companies.

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com.

The Company previously announced it had successfully met the first performance milestone in the distribution and development agreement signed with Zimmer Biomet on July 20, 2020. In addition to acquiring exclusive global distribution rights to NeuroOne’s Evo™ (Evo) patented electrode technology, the partnership also offered the potential for NeuroOne to earn back-end milestone payments if certain events were met within a specified time frame.

NeuroOne received FDA clearance for its Evo cortical technology in November 2019.

In partnership with Mayo Clinic, Wisconsin Alumni Research Foundation (WARF) and other prominent academic medical centers, the Company began developing its cortical electrode technology in 2015. The Company initially focused its efforts on the epilepsy and intraoperative tumor monitoring markets. NeuroOne intends to continue to develop the technology for use in therapeutic applications for Parkinson’s disease, epilepsy and pain management due to failed back surgery procedures.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-present-at-access-to-giving-virtual-conference-on-july-15-2021-at-2-pm-et-301326578.html

SOURCE NeuroOne Medical Technologies Corporation